doi:10.3969/j.issn.1004-583X.2024.08.014

Abstract

CLC Number:

R593.2

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.08.014

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I8/763

Figures/Tables 1

References 47

[1]	Batani V, Lanzillotta M, Mahajne J, et al. Association of IgG4-related disease and systemic rheumatic disorders[J]. Eur J Intern Med, 2023, 111: 63-68. doi: 10.1016/j.ejim.2023.03.015 pmid: 36935250
[2]	Della-Torre E, Mancuso G, Lanzillotta M, et al. Urgent manifestations of immunoglobulin G(4)-related disease[J]. Scand J Rheumatol, 2021, 50(1): 48-51.
[3]	Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis[J]. Dig Dis Sci, 1995, 40(7): 1561-1568.
[4]	Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis[J]. N Engl J Med, 2001, 344(10): 732-738.
[5]	Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease[J]. J Gastroenterol, 2003, 38(10): 982-984. doi: 10.1007/s00535-003-1175-y pmid: 14614606
[6]	Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4rd): General concept and details[J]. Mod Rheumatol, 2012, 22(1): 1-14. doi: 10.1007/s10165-011-0508-6 pmid: 21881964
[7]	Naitoh I, Kamisawa T, Tanaka A, et al. Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort[J]. Dig Liver Dis, 2021, 53(10): 1308-1314.
[8]	Tanaka A, Mori M, Kubota K, et al. Epidemiological features of immunoglobulin G4-related sclerosing cholangitis in Japan[J]. J Hepatobiliary Pancreat Sci, 2020, 27(9): 598-603.
[9]	Ng WR, Lau NS, Fadia M, et al. IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma[J]. J Surg Case Rep, 2023, 2023(11): rjad621.
[10]	Liu Q, Li B, Li Y, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis[J]. Gut, 2022, 71(5): 899-909.
[11]	Nakazawa T, Ohara H, Sano H, et al. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography[J]. Pancreas, 2006, 32(2): 229.
[12]	Naitoh I, Nakazawa T. Classification and diagnostic criteria for IgG4-related sclerosing cholangitis[J]. Gut Liver, 2022, 16(1): 28-36.
[13]	Nakazawa T, Kamisawa T, Okazaki K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012)[J]. J Hepatobiliary Pancreat Sci, 2021, 28(3): 235-242.
[14]	Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (Rcd) criteria for IgG4-Rd[J]. Mod Rheumatol, 2021, 31(3): 529-33. doi: 10.1080/14397595.2020.1859710 pmid: 33274670
[15]	Radford-Smith DE, Selvaraj EA, Peters R, et al. A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis[J]. Liver Int, 2022, 42(6): 1344-1354. doi: 10.1111/liv.15192 pmid: 35129255
[16]	Abraham SC, Cruz-Correa M, Argani P, et al. Lymphoplasmacytic chronic cholecystitis and biliary tract disease in patients with lymphoplasmacytic sclerosing pancreatitis[J]. Am J Surg Pathol, 2003, 27(4): 441-451. pmid: 12657928
[17]	Zhang R, Lin HM, Cai ZX, et al. Clinical strategies for differentiating IgG4-related cholecystitis from gallbladder carcinoma to avoid unnecessary surgical resection[J]. Sci China Life Sci, 2020, 63(5): 764-670. doi: 10.1007/s11427-019-9539-6 pmid: 31321666
[18]	Harada Y, Mihara K, Amemiya R, et al. Isolated IgG4-related cholecystitis with localized gallbladder wall thickening mimicking gallbladder cancer: A case report and literature review[J]. BMC Gastroenterol, 2022, 22(1): 99. doi: 10.1186/s12876-022-02179-z pmid: 35246051
[19]	Khosroshahi A, Wallace ZS, Crowe J L, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699.
[20]	Umemura T, Zen Y, Hamano H, et al. Immunoglobin G4-hepatopathy: Association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis[J]. Hepatology, 2007, 46(2): 463-471. pmid: 17634963
[21]	Nakanuma Y, Ishizu Y, Zen Y, et al. Histopathology of IgG4-related autoimmune hepatitis and IgG4-related hepatopathy in IgG4-related disease[J]. Semin Liver Dis, 2016, 36(3): 229-241. doi: 10.1055/s-0036-1584320 pmid: 27466793
[22]	Umemura T, Zen Y, Hamano H, et al. IgG4 associated autoimmune hepatitis: A differential diagnosis for classical autoimmune hepatitis[J]. Gut, 2007, 56(10): 1471-1412. pmid: 17504944
[23]	Umemura T, Zen Y, Nakanuma Y, et al. Another cause of autoimmune hepatitis[J]. Hepatology, 2010, 52(1): 389-390. doi: 10.1002/hep.23730 pmid: 20578154
[24]	Umemura T, Zen Y, Hamano H, et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis[J]. J Gastroenterol, 2011, 46(Suppl 1): 48-55.
[25]	Miyagi A, Fujimoto D, Yoshikawa A, et al. A rare case of fibrohistiocytic hepatic inflammatory pseudotumor with cholecystocholangitis showing positive IgG4 staining[J]. Clin J Gastroenterol, 2022, 15(5): 975-980.
[26]	Jang SY, Han YS, Lee SY, et al. A case of hepatic immunoglobulin G4-related disease presenting as an inflammatory pseudotumor and sclerosing cholangitis[J]. Diagnostics (Basel), 2022, 12(6):1497.
[27]	Kim F, Yamada K, Inoue D, et al. IgG4-related tubulointerstitial nephritis and hepatic inflammatory pseudotumor without hypocomplementemia[J]. Intern Med, 2011, 50(11): 1239-1244.
[28]	Legkiy O, Wajda J 'Cwierz A, et al. Hepatic inflammatory pseudotumor related with IgG4[J]. Gastroenterol Hepatol, 2019, 42(3): 176-177. doi: S0210-5705(18)30088-8 pmid: 29655493
[29]	Cui X, Xu W, Zhang Y, et al. Autoimmune pancreatitis with pancreatic calculi and pseudocyst: A case report[J]. J Int Med Res, 2021, 49(5): 3000605211014798.
[30]	Zhao Y, Li F, An N, et al. Atypical enhanced computed tomography signs of pancreatic cancer and its differential diagnosis from autoimmune pancreatitis[J]. Gland Surg, 2021, 10(1): 347-354. doi: 10.21037/gs-20-821 pmid: 33633991
[31]	李兆申, 李汛, 郭晓钟, 等. 中国自身免疫性胰腺炎诊治指南(上海,2023)[J]. 临床肝胆病杂志, 2024, 40(7): 1312-1320.
[32]	Noguchi K, Nakai Y, Mizuno S, et al. Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus[J]. J Gastroenterol, 2020, 55(2): 198-204. doi: 10.1007/s00535-019-01615-4 pmid: 31471733
[33]	Kawa S, Kamisawa T, Notohara K, et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: Revision of Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011[J]. Pancreas, 2020, 49(1): e13-e14.
[34]	丁航, 刘源, 张连峰, 等. 血清IgG4对IgG4相关性疾病诊断价值的meta分析[J]. 临床荟萃, 2021, 36(7): 587-594.
[35]	Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020[J]. J Gastroenterol, 2022, 57(4): 225-245.
[36]	Löhr JM, Beuers U, Vujasinovic M, et al. European guideline on IgG4-related digestive disease-Ueg and Sgf evidence-based recommendations[J]. United European Gastroenterol J, 2020, 8(6): 637-666.
[37]	Cuéllar M C, Gutiérrez M, Herrera A, et al. IgG4-Related Disease. Report of 52 Patients[J]. Rev Med Chil, 2022, 150(6): 705-710. doi: 10.4067/S0034-98872022000600705 pmid: 37906904
[38]	周佳鑫, 张文. 《IgG4相关性疾病诊治中国专家共识》解读[J]. 临床肝胆病杂志, 2021, 37(9): 2062-2065.
[39]	Zhang X, Zeng Z, Tian H, et al. Clinical features and relapse risks factors of IgG4 related disease: A single-center retrospective study[J]. Clin Exp Med, 2023, 23(7): 3527-3238. doi: 10.1007/s10238-023-01123-z pmid: 37392248
[40]	Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-Rd (Wins IgG4-Rd): An investigator-initiated, multicentre, open-label, randomised controlled trial[J]. Ann Rheum Dis, 2024, 83(5): 651-660. doi: 10.1136/ard-2023-224487 pmid: 38216319
[41]	Alsalamah NI, Alhrabi B, Alhumaily N, et al. Efficacy and safety of glucocorticoid monotherapy versus the combination of glucocorticoid and immunosuppressive agents for immunoglobulin G4-related disease: A systematic review and meta-analysis[J]. Cureus, 2023, 15(10): e47099.
[42]	Yoshifuji H, Umehara H. Glucocorticoids in the treatment of IgG4-related disease-prospects for new international treatment guidelines[J]. Mod Rheumatol, 2023, 33(2): 252-257.
[43]	Cai S, Hu Z, Chen Y, et al. Blys/april dual inhibition for IgG4-Rd: A prospective single-arm clinical trial of telitacicept[J]. Ann Rheum Dis, 2023, 82(6): 881-883.
[44]	Nakayamada S, Tanaka Y. Development of targeted therapies in IgG4-related disease[J]. Mod Rheumatol, 2023, 33(2): 266-270.
[45]	Peng Y, Zhang W. Abatacept for IgG4-related disease: Therapeutic prospects according to disease immunophenotype[J]. Lancet Rheumatol, 2022, 4(2): e75-e76.
[46]	Liu Y, Yang F, Chi X, et al. Needle biopsy compared with surgical biopsy: Pitfalls of small biopsy in histologial diagnosis of IgG4-related disease[J]. Arthritis Res Ther, 2021, 23(1): 54. doi: 10.1186/s13075-021-02432-y pmid: 33568210
[47]	Timakova AA, Radenska-Lopovok SG. Differential diagnosis of IgG4-related disease[J]. Arkh Patol, 2023, 85(2): 60-65. doi: 10.17116/patol20238502160 pmid: 37053356

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 47

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Song Yijing, Li Jian, Song Qin, Shao Li. Predictive value of C-reactive protein combined with triglyceride glucose index for coronary heart disease risk in patients with rheumatoid arthritis [J]. Clinical Focus, 2024, 39(6): 506-511.
[2]	. [J]. Clinical Focus, 2024, 39(5): 475-480.
[3]	Zhu Suhua, Xu Shengqiu. Review: efficacy and pharmacogenomics of leflunomide plus methotrexate versus iguratimod plus methotrexate in the treatment of rheumatoid arthritis [J]. Clinical Focus, 2024, 39(4): 304-313.
[4]	Zhang Xiaoyang, Zang Meirong, Suo Jing, Meng Jianbo, Song Xiaoning, Wang Jinkai. Ankylosing spondylitis combined with acute promyelocytic leukaemia and disseminated intravascular coagulation: A case report and literature review [J]. Clinical Focus, 2024, 39(4): 342-346.
[5]	Gong Sijing, Yang Yushu, Guo Huifang, Ding Meng, Wang Wei, Gao Lixia. Analysis of the clinical value for anti-Ro52 and anti-Ro60 antibodies in connective tissue disease [J]. Clinical Focus, 2024, 39(3): 227-233.
[6]	Song Jialiang, Jiang Yingjie, Kong Ruina, Cai Qing, Gao Jie. IgG4-related diseases characterized by increased IgE level and eosinophil count with multiple lymphadenopathy: A case report [J]. Clinical Focus, 2024, 39(1): 57-60.
[7]	. [J]. Clinical Focus, 2024, 39(1): 92-96.
[8]	He Peihua, Zhou Xingfu, Hong Weihong, Wang Lichun, Liu Sujun, Jin Yuyan, Zeng Jiahao, Liu Lichang. Clinical analysis of 4 cases of IgG4-related kidney disease [J]. Clinical Focus, 2023, 38(11): 1016-1021.
[9]	. [J]. Clinical Focus, 2023, 38(10): 944-948.
[10]	. [J]. Clinical Focus, 2023, 38(8): 753-756.
[11]	. [J]. Clinical Focus, 2023, 38(7): 663-667.
[12]	. [J]. Clinical Focus, 2023, 38(3): 279-284.
[13]	Gao Ying, Han Zhongli, Wang Hongyan, Li Xiaofu. Magnetic resonance imaging characteristics of Andersson lesions associated with ankylosing spondylitis [J]. Clinical Focus, 2022, 37(10): 927-930.
[14]	Zhang Yueyue, Xie Meifang, Sun Gen. Rheumatoid arthritis complicated with T-cell large granular lymphocytic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(8): 728-732.
[15]	Lin Changyi, Song Minghui, Wu Peicheng. Effects of diagnosis age on clinical manifestations of polymyalgia rheumatica: A single center retrospective cohort study on 68 patients [J]. Clinical Focus, 2022, 37(7): 612-615.